Skip to main content
. 2011 Sep 28;22(3):633–641. doi: 10.1007/s00330-011-2288-y

Table 5.

Total number of participants, number of participants with at least one adverse event (AE), adverse drug reactions (ADR)/number of AE, and intensity of AE for CMC-001 and gadobenate dimeglumine enhanced liver MRI

CMC-001 Gadobenate dimeglumine
Total number of participants 20 20
Participants with at least one AE 19 (95%) 8 (40%)
Number of ADR/AE 24/31 3/9
Intensity of AE (mild/moderate/severe) 20/10/1 7/2/0